lumacaftor / ivacaftor

This medicine is authorised for use in the European Union.


Orkambi is a medicine used to treat cystic fibrosis in patients aged 2 years and above. Cystic fibrosis is an inherited disease that has severe effects on the lungs and the digestive system. It affects the cells that produce mucus and digestive juices. In cystic fibrosis, the secretions become thick and cause blockage. Build-up of thick and sticky secretions in the lungs causes inflammation and long-term infection. In the gut, blockage of the tubes from the pancreas slows down the digestion of food and causes poor growth.

Orkambi is used in patients who have a genetic mutation (change) called the F508del mutation. This mutation affects the gene for a protein called cystic fibrosis transmembrane conductance regulator (CFTR) which is involved in regulating the production of mucus and digestive juices. Orkambi is used in patients who have inherited the mutation from both parents.

Orkambi contains the active substances lumacaftor and ivacaftor.

This EPAR was last updated on 25/07/2022

Authorisation details

Product details
Agency product number
Active substance
  • Lumacaftor
  • ivacaftor
International non-proprietary name (INN) or common name
  • lumacaftor
  • ivacaftor
Therapeutic area (MeSH)
Cystic Fibrosis
Anatomical therapeutic chemical (ATC) code
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Vertex Pharmaceuticals (Ireland) Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Unit 49, Block F2, Northwood Court, Santry
Dublin 9, D09 T665

Product information

13/12/2021 Orkambi - EMEA/H/C/003954 - IG/1460

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other respiratory system products

Therapeutic indication

Orkambi tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene.

Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in children aged 2 years and older who are homozygous for the F508del mutation in the CFTR gene.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
2 ratings
1 rating
1 rating
2 ratings
2 ratings